Cybrexa Therapeutics reports that two posters featuring Cybrexa’s pipeline will be presented at the American Association for Cancer Research Virtual Annual Meeting II, which will be held June 22-24, 2020.
Abstracts are now available for CBX-12 and CBX-13.
CBX-12, Cybrexa’s lead candidate, is a conjugate that includes the highly potent and toxic topoisomerase I inhibitor exatecan. CBX-13 includes the highly potent maytansine DM4.